Allarity Therapeutics, Inc. (NASDAQ:ALLR – Get Rating) was the target of a large increase in short interest in December. As of December 15th, there was short interest totalling 112,200 shares, an increase of 2,852.6% from the November 30th total of 3,800 shares. Based on an average daily volume of 556,700 shares, the short-interest ratio is presently 0.2 days. Approximately 1.3% of the company's stock are sold short.

Allarity Therapeutics Price Performance

Shares of Allarity Therapeutics stock traded down $0.01 during trading on Wednesday, hitting $0.22. 7,272 shares of the company's stock traded hands, compared to its average volume of 1,628,587. Allarity Therapeutics has a 1 year low of $0.22 and a 1 year high of $12.86. The business has a 50-day simple moving average of $0.47 and a 200-day simple moving average of $0.97. The company has a current ratio of 0.47, a quick ratio of 0.47 and a debt-to-equity ratio of 0.73.

Allarity Therapeutics (NASDAQ:ALLR – Get Rating) last released its quarterly earnings data on Friday, October 7th. The company reported ($0.72) earnings per share for the quarter. As a group, sell-side analysts anticipate that Allarity Therapeutics will post -1.62 earnings per share for the current year.

Institutional Trading of Allarity Therapeutics

About Allarity Therapeutics

(Get Rating)

Allarity Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.

Read More

• Get a free copy of the StockNews.com research report on Allarity Therapeutics (ALLR)
• The Top Three Stocks Analysts Say To Buy
• Can Dick's Sporting Goods Stock Score Another Win In Q4?
• Why Did Immutep Ltd Stock Soar Recently?
• Yum! Brands Looks Tasty in 2023
• 3 Industrial Stocks to Help Build Your 2023 Watchlist

Receive News & Ratings for Allarity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allarity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.